Therapeutic Classification: antianginals, antihypertensives
Pharmacologic Classification: calcium channel blockers
Absorption: Well absorbed following oral administration but extensively metabolized, resulting in ↓ bioavailability. IV administration results in complete bioavailability.
Distribution: Unknown.
Half-Life: 24 hr.
(cardiovascular effects)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 20 min | 0.52 hr | 8 hr |
IV | within min | 45 min | 50 hr‡ |
‡Following discontinuation.
Contraindicated in:
Use Cautiously in:
CV: peripheral edema, ARRHYTHMIA, bradycardia, chest pain, HF, hypotension, palpitations, syncope, tachycardia
Derm: dermatitis, erythema multiforme, flushing, ↑sweating, photosensitivity, pruritus/urticaria, rash, STEVENS-JOHNSON SYNDROME
EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus
Endo: gynecomastia, hyperglycemia
GI: anorexia, constipation, diarrhea, dry mouth, dyspepsia, ↑liver enzymes, nausea, vomiting
GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency
Hemat: anemia, leukopenia, thrombocytopenia
MS: joint stiffness, muscle cramps
Neuro: abnormal dreams, anxiety, confusion, dizziness, drowsiness, dysgeusia, headache, jitteriness, nervousness, paresthesia, psychiatric disturbances, tremor, weakness.
Resp: cough, dyspnea, shortness of breath
Misc: gingival hyperplasia
Drug-drug:
Lab Test Considerations:
IV Administration: